Status:
COMPLETED
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Lead Sponsor:
University of Rochester
Conditions:
Cancer
Eligibility:
All Genders
70+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether information regarding GA and GA-driven interventions improves outcomes in older cancer patients receiving first-line or second-line chemotherapy by co...
Detailed Description
Although cancer is very common in older patients, the optimal treatment for cancer for this subset of patients is not well established. As a result of lack of knowledge on the safety and efficacy of c...
Eligibility Criteria
Inclusion
- Have a diagnosis of solid tumor malignancy or lymphoma
- Have advanced cancer
- Have received a recommendation for first or second line treatment with chemotherapy by their primary oncologist. Treatment regimens may include chemotherapy, chemoradiotherapy, targeted agents or monoclonal antibody.
- Planned chemotherapy for at least 3 months
- Be age 70 or older
- Have a live expectancy with treatment of 6 months or greater
- Able to provide informed consent or, if the physician deems the patient to not have decision-making capacity, a patient-designated health care proxy (that was pre-existing; prior to the patient losing decision-making capacity) must sign consent per institutional (University of Rochester and Research Subject Review Board) policies on consent for incapacitated/decisionally impaired subjects164,165
- Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
Exclusion
- Have surgery planned within 3 months of consent
- Have a planned referral to the geriatric oncology clinic within one month of treatment initiation
- Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01915056
Start Date
July 1 2013
End Date
January 1 2016
Last Update
May 1 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Highland Hospital
Rochester, New York, United States, 14620
2
Pluta Cancer Center
Rochester, New York, United States, 14623
3
University of Rochester Wilmot Cancer Center
Rochester, New York, United States, 14642